These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 15684021)

  • 1. A step forward in the everyday management of adults with community acquired pneumonia.
    Woodhead M; Verheij TJ
    BMJ; 2005 Feb; 330(7489):460. PubMed ID: 15684021
    [No Abstract]   [Full Text] [Related]  

  • 2. Is it possible to blind a trial for community-acquired pneumonia?
    Boucher HW
    Clin Infect Dis; 2008 Dec; 47 Suppl 3():S210-5. PubMed ID: 18986292
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Community-acquired pneumonia in Malaysian patients: addition of macrolide and the use of BTS "curb" index to assess severity.
    Loh LC
    Med J Malaysia; 2006 Mar; 61(1):128-30. PubMed ID: 16708753
    [No Abstract]   [Full Text] [Related]  

  • 4. Fluoroquinolones in the management of community-acquired pneumonia.
    Albertson TE; Dean NC; El Solh AA; Gotfried MH; Kaplan C; Niederman MS
    Int J Clin Pract; 2010 Feb; 64(3):378-88. PubMed ID: 20456176
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effectiveness of beta lactam antibiotics compared with antibiotics active against atypical pathogens in non-severe community acquired pneumonia: meta-analysis.
    Mills GD; Oehley MR; Arrol B
    BMJ; 2005 Feb; 330(7489):456. PubMed ID: 15684024
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Treatment of community-acquired pneumonia in adults: ertapenem versus cefditoren?].
    Torralba MÁ; Matía M; Gómez del Valle C; Pérez-Calvo JI
    Med Clin (Barc); 2010 Oct; 135(12):576-7. PubMed ID: 19819496
    [No Abstract]   [Full Text] [Related]  

  • 7. A study evaluating the efficacy, safety, and tolerability of ertapenem versus ceftriaxone for the treatment of community-acquired pneumonia in adults.
    Ortiz-Ruiz G; Caballero-Lopez J; Friedland IR; Woods GL; Carides A;
    Clin Infect Dis; 2002 Apr; 34(8):1076-83. PubMed ID: 11914996
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Community acquired pneumonia.
    Loeb M
    Clin Evid; 2002 Jun; (7):1358-68. PubMed ID: 12230751
    [No Abstract]   [Full Text] [Related]  

  • 9. Ertapenem versus ceftriaxone for the treatment of community-acquired pneumonia in adults: combined analysis of two multicentre randomized, double-blind studies.
    Ortiz-Ruiz G; Vetter N; Isaacs R; Carides A; Woods GL; Friedland I
    J Antimicrob Chemother; 2004 Jun; 53 Suppl 2():ii59-66. PubMed ID: 15150184
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Short-course beta-lactam treatment for community-acquired pneumonia.
    Stralin K; Sjöberg L; Holmberg H
    Clin Infect Dis; 2004 Mar; 38(5):766-7. PubMed ID: 14986269
    [No Abstract]   [Full Text] [Related]  

  • 11. Azithromycin extended-release (Zmax) for sinusitis and pneumonia.
    Obstet Gynecol; 2006 Jan; 107(1):180-2. PubMed ID: 16394059
    [No Abstract]   [Full Text] [Related]  

  • 12. Diagnosis and management of community-acquired pneumonia in adults.
    Watkins RR; Lemonovich TL
    Am Fam Physician; 2011 Jun; 83(11):1299-306. PubMed ID: 21661712
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Are new antibiotics better than beta-lactams for non-critical inpatients with community-acquired pneumonia?
    Reyes B T; Ortega G M; Saldías P F
    Medwave; 2016 Aug; 16 Suppl 3():e6499. PubMed ID: 27512983
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Moxifloxacin monotherapy versus beta-lactam-based standard therapy for community-acquired pneumonia: a meta-analysis of randomised controlled trials.
    An MM; Zou Z; Shen H; Gao PH; Cao YB; Jiang YY
    Int J Antimicrob Agents; 2010 Jul; 36(1):58-65. PubMed ID: 20400271
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Severe community-acquired pneumonia in adults: current antimicrobial chemotherapy.
    Niven DJ; Laupland KB
    Expert Rev Anti Infect Ther; 2009 Feb; 7(1):69-81. PubMed ID: 19622058
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of macrolide therapy on mortality in severe sepsis caused by pneumonia.
    van der Eerden MM; Boersma WG
    Eur Respir J; 2009 Aug; 34(2):521. PubMed ID: 19648530
    [No Abstract]   [Full Text] [Related]  

  • 17. [Initial treatment can lighten low-severity community-acquired pneumonia].
    Wasielewski S
    Med Monatsschr Pharm; 2005 Nov; 28(11):413. PubMed ID: 16309029
    [No Abstract]   [Full Text] [Related]  

  • 18. Overview of recent studies of community-acquired pneumonia.
    Higgins K; Singer M; Valappil T; Nambiar S; Lin D; Cox E
    Clin Infect Dis; 2008 Dec; 47 Suppl 3():S150-6. PubMed ID: 18986282
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and tolerability of ertapenem versus ceftriaxone in a double-blind study performed in children with complicated urinary tract infection, community-acquired pneumonia or skin and soft-tissue infection.
    Arguedas A; Cespedes J; Botet FA; Blumer J; Yogev R; Gesser R; Wang J; West J; Snyder T; Wimmer W;
    Int J Antimicrob Agents; 2009 Feb; 33(2):163-7. PubMed ID: 18945594
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Does empirical therapy with a fluoroquinolone or the combination of a β-lactam plus a macrolide result in better outcomes for patients admitted to the general ward?
    Ruhe J; Mildvan D
    Infect Dis Clin North Am; 2013 Mar; 27(1):115-32. PubMed ID: 23398869
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.